Supraventricular Arrhythmias in Patients With Pulmonary Arterial Hypertension
| Autor: | Margherita Cannillo, Walter Grosso Marra, Sebastiano Gili, Lorena Mercante, Daniela Libertucci, Fiorenzo Gaita, Mara Morello, Sebastiano Marra, Davide Salera, Elisa Mistretta, Arianna Bissolino, Fabrizio D'Ascenzo, Domenica Zema, Enrico Fusaro |
|---|---|
| Rok vydání: | 2015 |
| Předmět: |
Male
Supraventricular medicine.medical_specialty Hypertension Pulmonary Hemodynamics Heart Rate Risk Factors Interquartile range Tachycardia Diffusing capacity Internal medicine Tachycardia Supraventricular medicine Humans Aged Retrospective Studies business.industry Female Follow-Up Studies Incidence Italy Middle Aged Cardiology and Cardiovascular Medicine Incidence (epidemiology) Hazard ratio Retrospective cohort study Pulmonary medicine.disease Pulmonary hypertension Confidence interval Hypertension Cardiology business |
| Zdroj: | The American Journal of Cardiology. 116:1883-1889 |
| ISSN: | 0002-9149 |
| DOI: | 10.1016/j.amjcard.2015.09.039 |
| Popis: | The onset of supraventricular arrhythmias (SVA) may be associated with clinical worsening in patients with pulmonary arterial hypertension (PAH). However, limited data have been reported, especially at long-term follow-up. Aim of this study was to investigate the incidence of SVA in our patients with PAH, the risk factors correlated to their onset and the prognostic impact. All consecutive patients with PAH without history of SVA were enrolled. Incidence of new SVA was investigated and also the risk factors for SVA. Primary end point of the study was the impact of SVA on a composite of all-cause mortality and re-hospitalization, whereas mortality was the secondary end point. Seventy-seven patients were enrolled. No significant differences in the clinical or instrumental baseline characteristics between the 2 study groups were reported. During a median follow-up of 35 months (interquartile range 21.5 to 53.5), 17 (22%) patients experienced SVA. Development of SVA was associated with worsening of prognostic parameters at the follow-up: increasing of World Health Organization (WHO) functional class (p = 0.005) and N-terminal-pro-brain natriuretic peptide (NT-proBNP) (p = 0.018) and reduction of 6-minute walking distance (p = 0.048), tricuspid annular plane systolic excursion (TAPSE) (p = 0.041), and diffusing capacity of the lung for carbon monoxide (p = 0.025). The primary end point occurred in 13 patients (76%) in the SVA group and in 22 patients (37%) in the group without SVA (p = 0.004), whereas 9 patients (53%) among those with SVA died during the follow-up compared with 8 (13%) among those without (p = 0.001). At multivariate analysis, development of SVA was independently associated with an increased risk to meet the both primary (hazard ratio 2.13; 95% confidence interval 1.07 to 4.34; p = 0.031) and secondary (hazard ratio 4.1; 95% confidence interval 1.6 to 10.6; p = 0.004) end points. In conclusion, during the 3-year follow-up period, 1/3 of patients with PAH developed SVA, which was related to worsening of hemodynamic and functional parameter and independently predicted adverse prognosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect